Correspondence | Published:

The ORFeome Collaboration: a genome-scale human ORF-clone resource

Nature Methods volume 13, pages 191192 (2016) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Methods Enzymol. 328, 575–592 (2000).

  2. 2.

    MGC Project Team et al. Genome Res. 19, 2324–2333 (2009).

  3. 3.

    et al. Genome Res. 11, 422–435 (2001).

  4. 4.

    et al. Nat. Methods 8, 659–661 (2011).

  5. 5.

    et al. Cell 159, 1212–1226 (2014).

  6. 6.

    & Nat. Protoc. 10, 756–767 (2015).

Download references

Acknowledgements

The authors acknowledge valuable encouragement for initiating the OC from F. Collins (US National Institutes of Health) and E. Harlow (Harvard Medical School). Some of the cDNAs used as PCR templates for ORF cloning and other support were received from the German cDNA Consortium: K. Köhrer (University Düsseldorf, Germany), W. Ansorge (EMBL Heidelberg, Germany), H. Blöcker (Helmholtz Center Braunschweig, Germany), W. Mewes, C. Amid (Helmholtz Center Munich, Germany), J. Lauber, A. Bahr (Qiagen, Hilden, Germany), D. Heubner, R. Wambutt (Agowa, Berlin, Germany), B. Ottenwälder, B. Obermaier (Medigenomix, Ebersberg, Germany), H. Blum, H. Domdey (University Munich, Germany), I. Schupp, S. Bechtel and A. Poustka (DKFZ, Heidelberg, Germany). The German cDNA Consortium was funded by the Federal Ministry of Education and Research (BMBF) in the frame of the German Genome Project (DHGP) and the German National Genome Research Network (NGFN) programs (to S.W.). This work was supported by the Ellison Foundation (grant to M.V. and D.E.H.); the DFCI Institute (Sponsored Research funds to M.V. and D.E.H.); the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan (research grants to Y.H. at the RIKEN Omics Science Center and to P.C. at the RIKEN Center for Life Science Technologies); and the MEXT Genome Network Project (grant to Y.H.).

Author information

Affiliations

  1. Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.

    • Stefan Wiemann
    • , Anika Jöcker
    •  & Ruth Wellenreuther
  2. Genomics & Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany.

    • Stefan Wiemann
    • , Oliver Heil
    •  & Agnes Hotz-Wagenblatt
  3. IMAGE Consortium, Lawrence Livermore National Laboratories, Livermore, California, USA.

    • Christa Pennacchio
  4. Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.

    • Yanhui Hu
  5. Virginia G. Piper Center for Personalized Diagnostics (VGPCPD), Biodesign Institute, Arizona State University, Tempe, Arizona, USA.

    • Preston Hunter
    • , Jin Park
    • , Catherine Seiler
    • , Jason Steel
    •  & Joshua LaBaer
  6. DNAFORM Inc., Tsurumi-ku, Yokohama City, Kanagawa, Japan.

    • Matthias Harbers
  7. Division of Genomic Technologies, RIKEN Center for Life Science Technologies, RIKEN Yokohama Institute, Tsurumi-ku, Yokohama, Kanagawa, Japan.

    • Matthias Harbers
    •  & Piero Carninci
  8. Dharmacon, GE Healthcare, Lafayette, Colorado, USA.

    • Alexandra Amiet
    •  & Anja van Brabant Smith
  9. Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK.

    • Graeme Bethel
    •  & Ian Dunham
  10. Source BioScience, Nottingham, UK.

    • Melanie Busse
    •  & Tom Weaver
  11. UC Santa Cruz Genomics Institute, University of California, Santa Cruz, California, USA.

  12. Center for Cancer Systems Biology (CCSB), Dana‐Farber Cancer Institute, Boston, Massachusetts, USA.

    • Tong Hao
    • , Kourosh Salehi-Ashtiani
    • , Marc Vidal
    •  & David E Hill
  13. Department of Cancer Biology, Dana‐Farber Cancer Institute, Boston, Massachusetts, USA.

    • Tong Hao
    • , Kourosh Salehi-Ashtiani
    • , Marc Vidal
    •  & David E Hill
  14. Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.

    • Tong Hao
    • , Kourosh Salehi-Ashtiani
    • , Marc Vidal
    •  & David E Hill
  15. Dana-Farber–Harvard Cancer Center (DFHCC) DNA Resource Core and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.

    • J Wade Harper
  16. RIKEN Preventive Medicine & Diagnosis Innovation Program, RIKEN Yokohama Institute, Wako, Saitama, Japan.

    • Yoshihide Hayashizaki
    •  & Jun Kawai
  17. imaGenes GmbH, Berlin, Germany.

    • Steffen Hennig
    • , Christoph Koenig
    •  & Johannes Maurer
  18. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland, USA.

    • Wonhee Jang
    •  & Lukas Wagner
  19. Ressourcenzentrum für Genomforschung gGmbH, Berlin, Germany.

    • Bernhard Korn
  20. National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.

    • Cristen Lambert
    •  & Gary Temple
  21. HudsonAlpha Institute of Biotechnology, Huntsville, Alabama, USA.

    • Anita LeBeau
    •  & Blake Simmons
  22. GeneCopoeia, Inc., Rockville, Maryland, USA.

    • Sun Lu
    •  & Shuwei Yang
  23. Guangzhou FulenGen, Ltd., Guangdong, China.

    • Sun Lu
  24. Open Biosystems, Inc., Huntsville, Alabama, USA.

    • Troy Moore
    •  & Blake Simmons
  25. Kasusa DNA Research Institute, Kisarazu, Chiba, Japan.

    • Osamu Ohara
  26. Department of Biological Chemistry & Molecular Pharmacology, Harvard Institute of Proteomics, Harvard Medical School, Boston, Massachusetts, USA.

    • Andreas Rolfs
  27. Office of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

    • Daniela S Gerhard
  28. Department of Chemistry and Biochemistry, Arizona State University, Tempe, Arizona, USA.

    • Joshua LaBaer

Consortia

  1. The ORFeome Collaboration

Authors

    Competing interests

    Various coauthors work in companies that license, manufacture and sell research reagents including the ORF clones derived from human genes that are described in this manuscript. The following authors are commercial distributors of OC clones and thus declare competing financial interests: M.H., A.A., M.B., S.H., C.K., B.K., A.L., S.L., J.M., T.M., B.S., A.v.B.S., T.W. and S.Y.

    Corresponding authors

    Correspondence to Stefan Wiemann or Matthias Harbers or Marc Vidal or Joshua LaBaer or Gary Temple or David E Hill.

    Supplementary information

    PDF files

    1. 1.

      Supplementary Text

      Supplementary Note

    2. 2.

      Supplementary Data

      Background and structure of OC; description of OC clone collection; evaluation of gene coverage in functional categories; how to obtain OC clones; the OC clone annotation process.

    About this article

    Publication history

    Published

    DOI

    https://doi.org/10.1038/nmeth.3776

    Further reading

    Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing